Biology of the Human Graft‐versus‐Tumor Response and How to Exploit It

Warren, Edus H.

doi:10.1002/9781118416426.ch16

Cited by 2 publications

(2 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efficacy is mediated, in large part, through the graft versus leukemia (GvL) effect, and alloreactivity of donor T-cells against host leukemic cells. 1 Grafted donor immune cells recognize leukemic cells as foreign and eliminate them. Evidence for GvL comes from a number of observations: patients who relapse after allo-HCT can achieve remission after stopping immunosuppression or with donor lymphocyte infusions, allo-HCT with reduced intensity conditioning regimens can induce remission in acute myeloid leukemia (AML), T-cell depleted grafts have higher rates of relapse, and patients with AML who develop graft- versus -host disease (GVHD), especially chronic GVHD (cGVHD), 2 after allo-HCT have a lower rate of relapse.…”

Section: Introductionmentioning

confidence: 99%

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease

Abboud

Choi

Ruminski

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Allogeneic hematopoietic transplantation (allo-HCT) is a curative therapy for a variety of hematologic malignancies, primarily through immune-mediated clearance of malignant cells. This graft- versus-leukemia (GvL) effect is mediated by alloreactive donor T-cells against recipient malignant cells. Unfortunately, graft versus host disease is a potentially lethal complication of this procedure, also mediated by alloreactive donor T-cells against recipient normal tissues. Graft- versus-host disease (GVHD) remains a key contributor to nonrelapse mortality and long-term morbidity in patients undergoing allo-HCT. Reducing GVHD without interfering with – or ideally while enhancing – GvL, would improve outcomes and increase patient eligibility for allo-HCT. The JAK/STAT signaling pathway acts downstream of over 50 cytokines and is central to a wide variety of inflammatory pathways. These pathways play a role in the development and maintenance of GVHD throughout the disease process and within T-cells, B-cells, macrophages, neutrophils, and natural killer cells. Agents targeting JAK/STAT signaling pathways have shown clinical efficacy and gained US Food and Drug Administration approval for numerous diseases. Here, we review the preclinical and clinical evidence for the role of JAK/STAT signaling in the development and maintenance of GVHD and the utility of blocking agents at preventing and treating GVHD.

show abstract

Section: Introductionmentioning

confidence: 99%

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease

Abboud

Choi

Ruminski

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…O efeito imunoterápico do transplante de medula óssea é o grande diferencial entre os regimes autólogo e alogênico, e baseia-se na capacidade do sistema imunológico do doador de reconhecer e eliminar células tumorais remanescentes após o regime de condicionamento. O efeito imunológico do enxerto contra o tumor permite a cura de neoplasias resistentes ao tratamento quimioterápico, porém sua presença ou eficácia não são garantidas (WARREN, 2015). Saiba mais sobre os tipos de transplantes de precursores hematopoiéticos e suas indicações nos Estados Unidos no Box 15.1.…”

Section: Terapias Imunológicas Não Modificadas Geneticamenteunclassified

Tratado brasileiro de biotecnologia em saúde: da bancada ao leito

2024

View full text Add to dashboard Cite

Atua como vice -diretor de gestão e desenvolvimento institucional em Bio -Manguinhos/Fiocruz. Coordena a implantação de duas novas áreas fabris, os campis Santa Cruz e Ceará. Mestre em Economia Empresarial, com especialização em Planejamento, Programação e Controle de Produção e em Administração Pública. Graduado em Administração de Empresas. Foi diretor de Bio -Manguinhos/ Fiocruz de 2009 a 2017. Presidente da ALFOB, no seu segundo mandato, é membro do Conselho Científico da Hemobrás, membro do conselho de Administração do IBMP e Diretor Superintendente da FAP.

show abstract

Biology of the Human Graft‐versus‐Tumor Response and How to Exploit It

Cited by 2 publications

References 168 publications

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease

Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease

Tratado brasileiro de biotecnologia em saúde: da bancada ao leito

Contact Info

Product

Resources

About